Therefore, we suggest that GLP-1R agonists via BAT activation reduce both hyperlipidaemia and hyperglycaemia, and possibly even atherosclerosis [31], in addition to the effects of BAT activation on obesity. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.